Dermatology

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

In this Q&A interview at AAD 2026, Gold highlights various tips and strategies for healing scars among patients with skin of color.

This Q&A interview with Gold at AAD 2026 highlights notable takeaways from his portion of the session titled 'Acne Boot Camp.'

This summary of March 2026 highlights key news and developments in the dermatology news space.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

This Q&A interview at AAD 2026 highlights health information technologies and AI tools used in dermatology practices.

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

This Q&A interview with Grant-Kels highlights takeaways from her session on managing the needs of patients in dermatology practicers who are pregnant.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in nonsegmental vitiligo (NSV).

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.